CTOs on the Move


 
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.geron.com
  • 149 Commonwealth Drive
    Menlo Park, CA USA 94025
  • Phone: 650.473.7700

Executives

Name Title Contact Details
Brian Blood
Vice President Information Technology Profile
Andrew Grethlein
Executive Vice President and Chief Operating Officer Profile

Similar Companies

California Clinical Trials

CCT is a pioneer in the QTc field. We conducted our first study in 1998 with Pfizer's ziprasidone in patients with schizophrenia. Our staff includes experienced principal investigators, dedicated cardiologists, psychiatrists, experienced ECG

Superior Care Home-Nursing

Superior Care Home-Nursing is a Paducah, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soka Services

Soka Services LLC is a Pontiac, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jones Regional Medical Center

Jones Regional Medical Center is a Anamosa, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.